PURA Research Recommends Speculative BUY And $0.25 PPS With Potential To $0.35 On Sales Growth, Dividends and M&A
June 06 2019 - 2:38PM
InvestorsHub NewsWire
PURA Research Recommends
Speculative BUY And $0.25 PPS With Potential To $0.35 On Sales
Growth, Dividends and M&A
DALLAS, TX -- June 6, 2019 -- InvestorsHub
NewsWire -- Puration, Inc. (USOTC:
PURA) (“PURA”) today announced that Goldman Small Cap Research
has released a new research report recommending PURA as a
Speculative BUY with a $0.25 PPS Target. Goldman Small Cap
Research further reports that the shares of PURA “have the
potential to reach the $0.35 mark.” The report highlights
PURA’s growing EVERx CBD Sports Water sales and the coming
introduction of new beverages as well as the potential for the
company to exceed its 2019 sales targets through the pending
doubling of its production capacity and through planned
acquisitions. The report further details recent updates
intended to accelerate the issue of Nouveau (USOTC:
NOUV) stock to PURA shareholders in a dividend distribution.
Notably, the report points to the capacity and quality
improvements enabled by the addition of a new team member with
exceptional beverage industry professional experience.
Goldman Small Cap
Research Excerpt
“… a series of company initiatives and
industry events serve as catalysts to drive PURA’s volume higher
and the shares back to its 52-week high of $0.25. Depending upon
the timing and magnitude of the aforementioned events, we believe
that these shares have the potential to reach the $0.35
mark.”
See Full
Report:
PURA Goldman Small
Cap Research Report Including Analyst Credentials &
Disclosures
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From May 2024 to Jun 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Jun 2023 to Jun 2024